Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Summary

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)

Timeline

Start

2021-01-01

Primary completion

2023-12-14

Completion

2023-12-14

Drugs

Indications